Mining And Ores Tenders

Open House Discount Contracts 2022-20

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Acitretin (D05bb02) as Part of a So-Called Open House Model.

Medicines Containing the Active Substance Rotigotine (Atc: N04bc09)

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Epinephrine, Atc C01ca24 for the Period 07/01/2023 - 06/30/2025

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Oxycodone Naloxone (N02aa55) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Distigmin (N07aa03) as Part of a So-Called Open House Model.

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Fluticasone Vilanterol Umeclidinium, Atc R03al08 for the Period 07/01/2023 - 06/30/2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for the Active Substance Lenalidomide (Only N3 Sizes), Atc L04ax04 for the Period July 1St, 2023 - June 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Ustekinumab, Atc L04ac05 for the Period from July 1St, 2023 to June 30Th, 2025